These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 24220011)

  • 1. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
    Bau JT; Kang Z; Austin CA; Kurz EU
    Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HU-331 is a catalytic inhibitor of topoisomerase IIα.
    Regal KM; Mercer SL; Deweese JE
    Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
    Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
    Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
    Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.
    Kao YH; Hsieh HP; Chitlimalla SK; Pan WY; Kuo CC; Tsai YC; Lin WH; Chuang SE; Chang JY
    Anticancer Drugs; 2008 Feb; 19(2):151-8. PubMed ID: 18176111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
    Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
    PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα.
    Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE
    Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
    Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
    Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate specificity plays an important role in uncoupling the catalytic and scaffolding activities of rat testis DNA topoisomerase IIalpha.
    Bakshi R; Galande S; Muniyappa K
    J Biomol Struct Dyn; 2001 Apr; 18(5):749-60. PubMed ID: 11334111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
    Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
    Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
    Satterwhite DJ; White RL; Matsunami N; Neufeld KL
    Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism.
    Lindsey RH; Pendleton M; Ashley RE; Mercer SL; Deweese JE; Osheroff N
    Biochemistry; 2014 Oct; 53(41):6595-602. PubMed ID: 25280269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex.
    Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T
    Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.